3rd generation glp 1 agonist Five Unexpected New Uses for GLP-1 Receptor Agonists GLP-1R Agonists for Weight Loss

It is the foundation, not the destination

HM12525A) is also a unimolecular once weekly GLP-1 and glucagon agonist that has been investigated in people with obesity, T2D and MASLD/MASH

In a 10-week clinical trial, a daily dose of 20 mg oral semaglutide achieved a steady-state plasma concentration of 30 nM, and when daily dose of oral semaglutide was increased to 40 mg, the semaglutide plasma concentration reached about 60 nM (102), which was over a thousand times higher than the EC50 of semaglutide for GLP-1R activation (95)

This is simply because Ozempic drug trials focused on how it impacted blood sugar (like metformin does), while Wegovy drug trials focused on how it impacted weight

The majority of the population received only AOM semaglutide (88.6%) and a small percentage received prescriptions for both AOM semaglutide and AOM liraglutide (6.3%)